DiaMedica Therapeutics Inc
Company Profile
Business description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Contact
301 Carlson Parkway
Suite 210
MinneapolisMN55305
USAT: +1 763 496-5454
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
28
Stocks News & Analysis
stocks
Why I dislike dividend stocks
stocks
Chart of the Week: Ramsay Health Care margins to rebound
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,402.10 | 45.90 | 0.49% |
| CAC 40 | 8,077.00 | 157.38 | 1.99% |
| DAX 40 | 24,181.37 | 55.57 | -0.23% |
| Dow JONES (US) | 46,253.31 | 17.15 | -0.04% |
| FTSE 100 | 9,424.75 | 28.02 | -0.30% |
| HKSE | 25,890.01 | 20.59 | -0.08% |
| NASDAQ | 22,670.08 | 148.38 | 0.66% |
| Nikkei 225 | 48,012.39 | 339.72 | 0.71% |
| NZX 50 Index | 13,333.76 | 26.36 | 0.20% |
| S&P 500 | 6,671.06 | 26.75 | 0.40% |
| S&P/ASX 200 | 9,099.00 | 48.80 | 0.54% |
| SSE Composite Index | 3,911.78 | 0.43 | -0.01% |